Latest News and Press Releases

AVITA Medical announces new manufacturing agreement and amended distribution agreement with Stedical Scientific to further commercialization of PermeaDerm.

AVITA Medical announced that Jim Corbett, CEO, will present at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025, at 11:50 a.m. Eastern Time.

AVITA Medical invites shareholders and prospective investors to attend its investor webinar briefing and presentation on February 18, 2025 at 2:00PM PT.

AVITA Medical reported financial results for the fourth quarter and full year 2025.

AVITA Medical expects fourth quarter 2024 commercial revenue of approximately $18.4 million, reflecting growth of around 30% over the same period in 2023.

AVITA Medical receives FDA approval for RECELL GO mini, optimizing treatment for smaller wounds and expanding patient accessibility.

AVITA Medical announces FDA clearance for Cohealyx, a new collagen-based dermal matrix, expanding its addressable market.

AVITA Medical to present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time.

VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care...

AVITA Medical announces exclusive distribution agreement to expand the RECELL product platform to Australia and New Zealand.